<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7005185/results/search/disease/results.xml">
  <result pre="Reports2045-2322Nature Publishing Group UKLondon pmcid: 700518558837 doi: 10.1038/s41598-020-58837-3 : Article" exact="Mitochondrial" post="toxicity and body shape changes during nucleos(t)ide analogues administration"/>
  <result pre="body shape changes during nucleos(t)ide analogues administration in patients with" exact="chronic hepatitis" post="B http://orcid.org/0000-0001-6099-2273MadedduGiordanogiordano@uniss.it1FioreVito1MelisMichela1OrtuSilvia1MannuFranca2MureddaAlberto Augusto1GarrucciuGiovanni3BandieraFranco3ZaruSalvatore3BagellaPaola1CalvisiDiego Francesco4BabudieriSergio1[1], 0000 0001 2097 9138grid.11450.31Infectious and"/>
  <result pre="shape changes during nucleos(t)ide analogues administration in patients with chronic" exact="hepatitis" post="B http://orcid.org/0000-0001-6099-2273MadedduGiordanogiordano@uniss.it1FioreVito1MelisMichela1OrtuSilvia1MannuFranca2MureddaAlberto Augusto1GarrucciuGiovanni3BandieraFranco3ZaruSalvatore3BagellaPaola1CalvisiDiego Francesco4BabudieriSergio1[1], 0000 0001 2097 9138grid.11450.31Infectious and"/>
  <result pre="B http://orcid.org/0000-0001-6099-2273MadedduGiordanogiordano@uniss.it1FioreVito1MelisMichela1OrtuSilvia1MannuFranca2MureddaAlberto Augusto1GarrucciuGiovanni3BandieraFranco3ZaruSalvatore3BagellaPaola1CalvisiDiego Francesco4BabudieriSergio1[1], 0000 0001 2097 9138grid.11450.31Infectious and Tropical" exact="Diseases" post="Unit, Department of Medical, Surgical and Experimental Sciences, University"/>
  <result pre="study purpose was to evaluate mitochondrial (mt)DNA and RNA in" exact="peripheral" post="blood mononuclear cells (PBMCs) and body shape changes (BSC)"/>
  <result pre="BSC was evaluated through a questionnaire and clinical evaluation. A" exact="total" post="of 157 subjects were enrolled, of these 107 were"/>
  <result pre="showed significantly higher mtDNA/nuclear (n) DNA ratio (p = 0.000008) compared to" exact="Group C" post="and Group B (p = 0.002). Group B showed significantly higher"/>
  <result pre="mtDNA/nuclear (n) DNA ratio (p = 0.000008) compared to Group C and" exact="Group B" post="(p = 0.002). Group B showed significantly higher mtDNA/nDNA ratio compared"/>
  <result pre="ratio (p = 0.000008) compared to Group C and Group B (p = 0.002)." exact="Group B" post="showed significantly higher mtDNA/nDNA ratio compared to Group C"/>
  <result pre="(p = 0.002). Group B showed significantly higher mtDNA/nDNA ratio compared to" exact="Group C" post="(p = 0.017). Group A and B had significantly lower mtRNA/nRNA"/>
  <result pre="to Group C (p = 0.017). Group A and B had significantly" exact="lower" post="mtRNA/nRNA ratio compared to Group C (p = 0.00003 and p = 0.00006,"/>
  <result pre="A and B had significantly lower mtRNA/nRNA ratio compared to" exact="Group C" post="(p = 0.00003 and p = 0.00006, respectively). Tenofovir and entecavir showed less"/>
  <result pre="significantly more frequent in Group A [10/54 (18.5%)] compared to" exact="Group B" post="[3/53 (5.6%, p = 0.04)] and Group C [0/50, (p = 0.0009)]. In"/>
  <result pre="[10/54 (18.5%)] compared to Group B [3/53 (5.6%, p = 0.04)] and" exact="Group C" post="[0/50, (p = 0.0009)]. In conclusion, long-term NA therapy was associated"/>
  <result pre="differences in mtDNA and mtRNA levels. Tenofovir and entecavir showed" exact="lower" post="impact on alterations, compared to 1st generation NA. Subject"/>
  <result pre="impact on alterations, compared to 1st generation NA. Subject terms" exact="Hepatitis" post="B Viral infection Funding https://doi.org/10.13039/501100009873Regione Autonoma della Sardegna (Sardinia"/>
  <result pre="alterations, compared to 1st generation NA. Subject terms Hepatitis B" exact="Viral infection" post="Funding https://doi.org/10.13039/501100009873Regione Autonoma della Sardegna (Sardinia Region) LR7 N.7LR7"/>
  <result pre="compared to 1st generation NA. Subject terms Hepatitis B Viral" exact="infection" post="Funding https://doi.org/10.13039/501100009873Regione Autonoma della Sardegna (Sardinia Region) LR7 N.7LR7"/>
  <result pre="N.7LR7 N.7LR7 N.7LR7 N.7LR7 N.7LR7 N.7MadedduGiordanoFioreVitoMelisMichelaOrtuSilviaMannuFrancaMureddaAlberto AugustoGarrucciuGiovanniBandieraFrancoZaruSalvatoreBagellaPaolaCalvisiDiego FrancescoBabudieriSergio Introduction HBV" exact="infection" post="represents the most common cause of chronic liver disease"/>
  <result pre="FrancescoBabudieriSergio Introduction HBV infection represents the most common cause of" exact="chronic" post="liver disease worldwide, and surface antigen (HBsAg) carriers living"/>
  <result pre="Introduction HBV infection represents the most common cause of chronic" exact="liver disease" post="worldwide, and surface antigen (HBsAg) carriers living in Europe"/>
  <result pre="HBV infection represents the most common cause of chronic liver" exact="disease" post="worldwide, and surface antigen (HBsAg) carriers living in Europe"/>
  <result pre="high antiviral efficacy, but their long-term administration caused an increased" exact="viral" post="resistance3. Lamivudine and adefovir were co-administered until the approval"/>
  <result pre="contrast resistance4. Indefinite treatment duration is suggested for patients with" exact="chronic hepatitis" post="B (CHB) and advanced liver cirrhosis, but also in"/>
  <result pre="resistance4. Indefinite treatment duration is suggested for patients with chronic" exact="hepatitis" post="B (CHB) and advanced liver cirrhosis, but also in"/>
  <result pre="suggested for patients with chronic hepatitis B (CHB) and advanced" exact="liver cirrhosis," post="but also in asymptomatic, non viremic patients, as well"/>
  <result pre="well as sometimes in HBsAg negative patients, as an HBV" exact="infection" post="exacerbation prophylaxis, during immunosuppressive therapy to treat malignancies, haematological"/>
  <result pre="well as reversible renal impairment and lipodystrophy, possibly associated with" exact="cardiovascular" post="risk7. Some of these adverse effects are linked to"/>
  <result pre="has been widely used to study the NAs toxicity during" exact="HIV infection" post="treatment8,10–12, literature in the HBV field is lacking. The"/>
  <result pre="been widely used to study the NAs toxicity during HIV" exact="infection" post="treatment8,10–12, literature in the HBV field is lacking. The"/>
  <result pre="observed in anti-HIV treatment. Patients and Methods Patient population A" exact="total" post="of 157 CHB patients both naive and on antiviral"/>
  <result pre="factors for HBV infection. Demographic characteristics, therapeutic history and HBV" exact="infection" post="stage by calculating APRI and Child-Pugh scores, laboratory parameters"/>
  <result pre="parameters and HBV-DNA levels were obtained from clinical records. A" exact="complete" post="antiviral therapy history was collected. Total antiviral therapy duration"/>
  <result pre="from clinical records. A complete antiviral therapy history was collected." exact="Total" post="antiviral therapy duration was defined as the duration (months)"/>
  <result pre="the physician during the study visit. The possible signs of" exact="lipodystrophy" post="were related to peripheral lipoatrophy, central fat accumulation, and"/>
  <result pre="study visit. The possible signs of lipodystrophy were related to" exact="peripheral" post="lipoatrophy, central fat accumulation, and lipomatosis, including buffalo hump,"/>
  <result pre="lipomatosis, including buffalo hump, fat accumulation in abdomen, mammary region," exact="lipomatosis" post="and fat loss in the face, arms, legs and"/>
  <result pre="at least three body sites. Patients with history of decompensated" exact="cirrhosis" post="and HCC were excluded. Whole blood samples for mitochondrial"/>
  <result pre="blood samples for mitochondrial (mt) DNA and RNA quantification from" exact="peripheral" post="blood mononuclear cells (PBMCs) were obtained from each patient."/>
  <result pre="mononuclear cells (PBMCs) were obtained from each patient. Laboratory methods" exact="Total" post="DNA was extracted from PBMCs with Pure Link Genomic"/>
  <result pre="probe (5′-VIC TGTCTCGCTCCGTGGCCTTAGCTG-3′). Appropriate controls ensuring no amplification in the" exact="absence of" post="reverse transcriptase were performed for each sample. For analysis,"/>
  <result pre="categorical variables among groups was evaluated using usual chi-square or" exact="Fisher" post="exact test, when appropriate, whereas non-parametric Kruskall-Wallis and Mann-Whitney"/>
  <result pre="between continuous variables were studied using the Spearman’s correlation test." exact="Multiple" post="linear regression analysis was used to evaluate possible predictors"/>
  <result pre="mtRNA/nRNA ratio. Statistical significance was considered for p &amp;lt; 0.05. Results A" exact="total" post="of 157 subjects (116 males and 41 females) were"/>
  <result pre="48 months (Interquartile range, IQR 24–60) and with a median" exact="total" post="therapy duration of 60 months (IQR 40–108), 53 were"/>
  <result pre="Among NAs treated patients, only 1/54 (4.5%) had a compensated" exact="cirrhosis" post="(Child Pugh A) and 5/54 (9.2%) complained of therapy-related"/>
  <result pre="No statistical difference was found in age, gender, BMI, known" exact="infection" post="duration, AST, ALT or creatinine levels and APRI score"/>
  <result pre="AST, ALT or creatinine levels and APRI score values. Median" exact="total" post="antiviral therapy duration was 37 months (IQR 24–60) in"/>
  <result pre="those treated with lamivudine + adefovir. The only statistically significant difference in" exact="total" post="therapy duration was between entecavir and tenofovir treated patients"/>
  <result pre="and tenofovir treated patients (p = 0.001) whereas, even if the median" exact="total" post="treatment duration was even longer, only a trend toward"/>
  <result pre="No statistical difference was found in age, gender, BMI, known" exact="infection" post="duration, AST, ALT or creatinine levels and APRI score"/>
  <result pre="(22–42) — AST (U/L) 23 (21–28) 22 (19–42) — HBV" exact="viral" post="load (U/L) &amp;lt;357 2,471 (478–5,848) — HBV DNA negative"/>
  <result pre="shape changes 10/54 (18.5%) 3/53 (5.6%) 0/50 (0%) Known HBV" exact="infection" post="duration (months) 146 (42–245) 152 (56–238) — Current antiviral"/>
  <result pre="Tenofovir 36 (30–54) — — Lamivudine + adefovir 57 (16–78) — —" exact="Total" post="antiviral therapy duration (months) 60 (40–108) — — Entecavir"/>
  <result pre="Group A patients showed significantly higher values (p = 0.000008) compared to" exact="Group C" post="subjects and to Group B patients (p = 0.002), as illustrated"/>
  <result pre="higher values (p = 0.000008) compared to Group C subjects and to" exact="Group B" post="patients (p = 0.002), as illustrated in Fig. 1. Group B"/>
  <result pre="to Group B patients (p = 0.002), as illustrated in Fig. 1." exact="Group B" post="patients showed significantly higher mtDNA/nDNA ratio when compared to"/>
  <result pre="B patients showed significantly higher mtDNA/nDNA ratio when compared to" exact="Group C" post="(p = 0.017). Figure 1 Comparison of mitochondrial DNA/nuclear DNA ratio"/>
  <result pre="range) and wiskers (range). Analyzing mtRNA/nRNA ratio, Group A and" exact="Group B" post="had significantly lower values when compared to Group C"/>
  <result pre="Analyzing mtRNA/nRNA ratio, Group A and Group B had significantly" exact="lower" post="values when compared to Group C (p = 0.00003 and p = 000006,"/>
  <result pre="and Group B had significantly lower values when compared to" exact="Group C" post="(p = 0.00003 and p = 000006, respectively), whereas no difference was evidenced"/>
  <result pre="lamivudine + adefovir (Fig. 2) compared to those receiving entecavir (p = 0.025), to" exact="Group B" post="(p = 0.00006) and Group C (p = 0.00003). Patients receiving tenofovir had"/>
  <result pre="to those receiving entecavir (p = 0.025), to Group B (p = 0.00006) and" exact="Group C" post="(p = 0.00003). Patients receiving tenofovir had significantly higher mtDNA/nDNA ratio"/>
  <result pre="tenofovir had significantly higher mtDNA/nDNA ratio levels when compared to" exact="Group B" post="(p = 0.0006) and Group C (p = 0.038) and had higher levels"/>
  <result pre="mtDNA/nDNA ratio levels when compared to Group B (p = 0.0006) and" exact="Group C" post="(p = 0.038) and had higher levels when compared to patients"/>
  <result pre="Patients receiving entecavir had significantly higher levels when compared to" exact="Group C" post="(p = 0.023), whereas no difference was found with Group B"/>
  <result pre="to Group C (p = 0.023), whereas no difference was found with" exact="Group B" post="(Fig. 2). Similarly, patients on therapy with lamivudine + adefovir showed"/>
  <result pre="(Fig. 2). Similarly, patients on therapy with lamivudine + adefovir showed significantly" exact="lower" post="mtRNA/nRNA ratio values when compared to patients receiving tenofovir"/>
  <result pre="(p = 0.027) and entecavir (p = 0.011). Patients receiving lamivudine + adefovir had also significantly" exact="lower" post="mtRNA/nRNA ratio levels in comparison with Group B (p = 0.0039)"/>
  <result pre="had also significantly lower mtRNA/nRNA ratio levels in comparison with" exact="Group B" post="(p = 0.0039) and Group C (p = 0.0000001). Furthermore, no statistical difference"/>
  <result pre="mtRNA/nRNA ratio levels in comparison with Group B (p = 0.0039) and" exact="Group C" post="(p = 0.0000001). Furthermore, no statistical difference between entecavir and tenofovir"/>
  <result pre="levels. Conversely, mtRNA/nRNA levels were negatively correlated with current and" exact="total" post="therapy duration (Spearman Rho = −0.34, p &amp;lt; 0.05). At multivariable analysis, we"/>
  <result pre="duration in HBV infected individuals but not with HBV known" exact="infection" post="duration. Regarding the body shape changes (BSC), 10/54 (18.5%)"/>
  <result pre="patients in the therapy Group A had clinical signs of" exact="lipodystrophy" post="(Fig. 3), compared to 3/53 patients (5.6%) untreated of"/>
  <result pre="lipodystrophy (Fig. 3), compared to 3/53 patients (5.6%) untreated of" exact="Group B" post="(p = 0.04) and in respect of group C (0/50, p = 0.0009)."/>
  <result pre="further stratifying patients according to NAs drugs, clinical manifestations of" exact="lipodystrophy" post="were observed in 7/20 (35%) patients receiving lamivudine + adefovir, in"/>
  <result pre="the presence of BSC between patients receiving lamivudine + adefovir (7/20) and" exact="Group B" post="(3/53), the difference appears to be statistically significant (p = 0.0032)."/>
  <result pre="with BSC had significantly higher levels of mtDNA (p = 0.018) and" exact="lower" post="levels of mtRNA when compared to those without NAs"/>
  <result pre="months (IQR 17–70) in patients without BSC (p = 0.045). Furthermore, the" exact="total" post="median duration of NA treatment was 104 months (IQR"/>
  <result pre="therapy. In studies conducted among HIV-infected patients, the prevalence of" exact="lipodystrophy" post="greatly varies depending on diagnostic criteria used, but up"/>
  <result pre="condition13,14. The first anti-HIV drugs to be clinically associated with" exact="lipodystrophy" post="were protease inhibitors (PIs)15, and this relationship was later"/>
  <result pre="was subsequently observed to be associated with the onset of" exact="lipodystrophy" post="and lactic acidosis17, mainly as a consequence of inhibition"/>
  <result pre="mitochondria18,19. BSCs have also been associated to the onset of" exact="metabolic syndrome" post="and increased cardiovascular risk in HIV-infected patients receiving HAART20,21."/>
  <result pre="BSCs have also been associated to the onset of metabolic" exact="syndrome" post="and increased cardiovascular risk in HIV-infected patients receiving HAART20,21."/>
  <result pre="been associated to the onset of metabolic syndrome and increased" exact="cardiovascular" post="risk in HIV-infected patients receiving HAART20,21. Mitochondrial dysfunction is"/>
  <result pre="syndrome and increased cardiovascular risk in HIV-infected patients receiving HAART20,21." exact="Mitochondrial" post="dysfunction is increasingly implicated in human diseases, ageing, and"/>
  <result pre="rarely associated with clinical signs of mitochondrial damage, such as" exact="lactic acidosis" post="and mostly in patients with decompensated cirrhosis or receiving"/>
  <result pre="associated with clinical signs of mitochondrial damage, such as lactic" exact="acidosis" post="and mostly in patients with decompensated cirrhosis or receiving"/>
  <result pre="such as lactic acidosis and mostly in patients with decompensated" exact="cirrhosis" post="or receiving a combination treatment. Cohort studies and clinical"/>
  <result pre="and clinical trials failed to detect an increased risk of" exact="lactic acidosis" post="in entecavir recipients30. Furthermore, to our knowledge, tenofovir has"/>
  <result pre="clinical trials failed to detect an increased risk of lactic" exact="acidosis" post="in entecavir recipients30. Furthermore, to our knowledge, tenofovir has"/>
  <result pre="Furthermore, to our knowledge, tenofovir has never been associated with" exact="lactic acidosis" post="in HBV-infected patients. Future strategies for CHB treatment will"/>
  <result pre="to our knowledge, tenofovir has never been associated with lactic" exact="acidosis" post="in HBV-infected patients. Future strategies for CHB treatment will"/>
  <result pre="include oral NAs in patients who are at risk for" exact="disease" post="progression or for HBV reactivation prophylaxis31. However, the impact"/>
  <result pre="a reduction in the risk of reactivation in patients with" exact="lymphoma" post="treated with a combination of adefovir/lamivudine, when compared to"/>
  <result pre="lack of correlation with other factors, such as age, BMI," exact="viral" post="load and infection duration. We found that patients receiving"/>
  <result pre="with other factors, such as age, BMI, viral load and" exact="infection" post="duration. We found that patients receiving lamivudine + adefovir had higher"/>
  <result pre="tenofovir, suggesting that the impact on mitochondrial damage could be" exact="lower" post="with 2nd generation NAs. Altogether, our results indicate a"/>
  <result pre="antiviral therapy may have greater effects on infant mtDNA levels." exact="Mitochondrial" post="dysfunction in HIV patients has not always been associated"/>
  <result pre="depletion alone, are also likely, as has been recently suggested36,38." exact="HIV infection" post="itself has been associated with decreased mtDNA levels and"/>
  <result pre="alone, are also likely, as has been recently suggested36,38. HIV" exact="infection" post="itself has been associated with decreased mtDNA levels and"/>
  <result pre="oxidative stress and/or a pro-inflammatory environment40,41. Our data suggest a" exact="limited" post="role for HBV infection itself, as opposed to that"/>
  <result pre="pro-inflammatory environment40,41. Our data suggest a limited role for HBV" exact="infection" post="itself, as opposed to that of HIV, in determining"/>
  <result pre="the similar results in HBV-negative controls. To our knowledge, only" exact="limited" post="data are available about mtRNA expression in PBMC from"/>
  <result pre="HBV infected patients9. In our study, we evidenced a significantly" exact="lower" post="mtRNA concentration in HBV infected patients exposed to NA"/>
  <result pre="negative controls. In addition, NA-treated patients with BSC have significantly" exact="lower" post="levels of mtRNA when compared with those without. We"/>
  <result pre="mtDNA levels after 4 weeks of zidovudine treatment in mouse" exact="muscle" post="cells43. In our study, the lack of correlation between"/>
  <result pre="levels may suggest that the alteration in transcription is not" exact="secondary" post="to changes in mtDNA, but could be rather a"/>
  <result pre="secondary to changes in mtDNA, but could be rather a" exact="primary" post="effect of NA therapy. Interestingly, patients receiving NAs with"/>
  <result pre="with BSC showed both significantly higher levels of mtDNA and" exact="lower" post="levels of mtRNA when compared to those without NAs,"/>
  <result pre="Among drugs, 2nd generation NA tenofovir and entecavir showed a" exact="lower" post="impact on mitochondrial alterations compared to 1st generation NA"/>
  <result pre="no competing interests. References References 1.SchaeferSHepatitis B virus taxonomy and" exact="hepatitis" post="B virus genotypesWorld J. Gastroenterol.200713142110.3748/wjg.v13.i1.1417206751 2.CuiXJChoYKSongBCInfluence of the basal"/>
  <result pre="the basal core promoter and precore mutation on replication of" exact="hepatitis" post="B virus and antiviral susceptibility of different genotypesJ. Med."/>
  <result pre="al.Randomized trial of lamivudine, adefovir, and the combination in HBeAg-positive" exact="chronic hepatitis" post="BClin. Res. Hepatol. Gastroenterol.20123659259710.1016/j.clinre.2012.05.01223069315 4.TanakaEMatsumotoAGuidelines for avoiding risks resulting"/>
  <result pre="trial of lamivudine, adefovir, and the combination in HBeAg-positive chronic" exact="hepatitis" post="BClin. Res. Hepatol. Gastroenterol.20123659259710.1016/j.clinre.2012.05.01223069315 4.TanakaEMatsumotoAGuidelines for avoiding risks resulting"/>
  <result pre="risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with" exact="chronic hepatitis" post="BHepatol. Res.2014441810.1111/hepr.1210823607862 5.CarosiGet al.Treatment of chronic hepatitis B: update"/>
  <result pre="resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic" exact="hepatitis" post="BHepatol. Res.2014441810.1111/hepr.1210823607862 5.CarosiGet al.Treatment of chronic hepatitis B: update"/>
  <result pre="in patients with chronic hepatitis BHepatol. Res.2014441810.1111/hepr.1210823607862 5.CarosiGet al.Treatment of" exact="chronic hepatitis" post="B: update of the recommendations from the 2007 Italian"/>
  <result pre="patients with chronic hepatitis BHepatol. Res.2014441810.1111/hepr.1210823607862 5.CarosiGet al.Treatment of chronic" exact="hepatitis" post="B: update of the recommendations from the 2007 Italian"/>
  <result pre="recommendations from the 2007 Italian WorkshopDig. Liver Dis.20114325926510.1016/j.dld.2010.10.01421276760 6.PattulloVPrevention of" exact="Hepatitis" post="B reactivation in the setting of immunosuppressionClin. Mol. Hepatol.20162221923710.3350/cmh.2016.002427291888"/>
  <result pre="in the setting of immunosuppressionClin. Mol. Hepatol.20162221923710.3350/cmh.2016.002427291888 7.CohenBHPharmacologic effects on" exact="Mitochondrial" post="functionDev. Disabil. Res. Rev.20101618919910.1002/ddrr.10620818734 8.BirkusGHitchcockMJCihlarTAssessment of mitochondrial toxicity in"/>
  <result pre="other nucleoside reverse transcriptase inhibitorsAntimicrob. Agents Chemother.20024671672310.1128/AAC.46.3.716-723.200211850253 9.ZhouLet al.Changes in" exact="Mitochondrial" post="Toxicity in Peripheral Blood Mononuclear Cells During Four-Year Administration"/>
  <result pre="inhibitorsAntimicrob. Agents Chemother.20024671672310.1128/AAC.46.3.716-723.200211850253 9.ZhouLet al.Changes in Mitochondrial Toxicity in Peripheral" exact="Blood" post="Mononuclear Cells During Four-Year Administration of Entecavir Monotherapy in"/>
  <result pre="During Four-Year Administration of Entecavir Monotherapy in Chinese Patients with" exact="Chronic" post="Hepatitis BMed. Sci. Monit.2015212058206310.12659/MSM.89293726176539 10.KampiraEet al.Peripheral blood mitochondrial DNA/nuclear"/>
  <result pre="Four-Year Administration of Entecavir Monotherapy in Chinese Patients with Chronic" exact="Hepatitis" post="BMed. Sci. Monit.2015212058206310.12659/MSM.89293726176539 10.KampiraEet al.Peripheral blood mitochondrial DNA/nuclear DNA"/>
  <result pre="toxicity in the era of HAART: evaluating venous lactate and" exact="peripheral" post="blood mitochondrial DNA in HIV-infected patients taking antiretroviral therapyJ."/>
  <result pre="al.Thymidine analogue withdrawal for lipoatrophic patients on protease-sparing therapy improves" exact="lipoatrophy" post="but compromises antiviral control: the PIILR extension studyAIDS.2002162489249110.1097/00002030-200212060-0002012461429 18.LeeHHanesJJohnsonKAToxicity"/>
  <result pre="SocioGVet al.CISAI study group. Identifying HIV patients with an unfavorable" exact="cardiovascular" post="risk profile in the clinical practice: results from the"/>
  <result pre="from the SIMONE studyJ. Infect.200857334010.1016/j.jinf.2008.03.00718436307 21.LakeJEet al.Regional fat deposition and" exact="cardiovascular" post="risk in HIV infection: the FRAM studyAIDS Care.20112392993810.1080/09540121.2010.54388521767228 22.ShuttTEShadelGSA"/>
  <result pre="Mutagen.20105136037920544879 23.BirkusGGibbsCSCihlarTComparative effects of adefovir and selected nucleoside inhibitors of" exact="hepatitis" post="B virus DNA polymerase on mitochondrial DNA in liver"/>
  <result pre="virus DNA polymerase on mitochondrial DNA in liver and skeletal" exact="muscle" post="cellsJ. Viral. Hepat.200310505410.1046/j.1365-2893.2003.00399.x12558912 24.LokASFMcMahonBJAASLD practice guideline: chronic hepatitis BHepatology.20074550753910.1002/hep.2151317256718"/>
  <result pre="liver and skeletal muscle cellsJ. Viral. Hepat.200310505410.1046/j.1365-2893.2003.00399.x12558912 24.LokASFMcMahonBJAASLD practice guideline:" exact="chronic hepatitis" post="BHepatology.20074550753910.1002/hep.2151317256718 25.MartinPet al.A Treatment Algorithm for the Management of"/>
  <result pre="and skeletal muscle cellsJ. Viral. Hepat.200310505410.1046/j.1365-2893.2003.00399.x12558912 24.LokASFMcMahonBJAASLD practice guideline: chronic" exact="hepatitis" post="BHepatology.20074550753910.1002/hep.2151317256718 25.MartinPet al.A Treatment Algorithm for the Management of"/>
  <result pre="hepatitis BHepatology.20074550753910.1002/hep.2151317256718 25.MartinPet al.A Treatment Algorithm for the Management of" exact="Chronic" post="Hepatitis B Virus Infection in the United States: 2015"/>
  <result pre="BHepatology.20074550753910.1002/hep.2151317256718 25.MartinPet al.A Treatment Algorithm for the Management of Chronic" exact="Hepatitis" post="B Virus Infection in the United States: 2015 UpdateClin."/>
  <result pre="Treatment Algorithm for the Management of Chronic Hepatitis B Virus" exact="Infection" post="in the United States: 2015 UpdateClin. Gastroenterol. Hepatol.20151320718710.1016/j.cgh.2015.07.00726188135 26.FleischerRDLokASMyopathy"/>
  <result pre="Infection in the United States: 2015 UpdateClin. Gastroenterol. Hepatol.20151320718710.1016/j.cgh.2015.07.00726188135 26.FleischerRDLokASMyopathy" exact="and neuropathy" post="associated with nucleos(t)ide analog therapy for hepatitisJ. Hepatol.20095178779110.1016/j.jhep.2009.06.01119665816 27.ChuCKet"/>
  <result pre="in the United States: 2015 UpdateClin. Gastroenterol. Hepatol.20151320718710.1016/j.cgh.2015.07.00726188135 26.FleischerRDLokASMyopathy and" exact="neuropathy" post="associated with nucleos(t)ide analog therapy for hepatitisJ. Hepatol.20095178779110.1016/j.jhep.2009.06.01119665816 27.ChuCKet"/>
  <result pre="trial results: telbivudine is superior to lamivudine in patients with" exact="chronic hepatitis" post="BGastroenterology.200913648649510.1053/j.gastro.2008.10.02619027013 30.LamperticoPet al.Review article: long-term safety of nucleoside and"/>
  <result pre="results: telbivudine is superior to lamivudine in patients with chronic" exact="hepatitis" post="BGastroenterology.200913648649510.1053/j.gastro.2008.10.02619027013 30.LamperticoPet al.Review article: long-term safety of nucleoside and"/>
  <result pre="HBV-monoinfected patientsAliment. Pharmacol. Ther.201644163410.1111/apt.1365927198929 31.collab: EASL Clinical Practice Guidelines:Management of" exact="chronic hepatitis" post="B virus infection European Association for the Study of"/>
  <result pre="patientsAliment. Pharmacol. Ther.201644163410.1111/apt.1365927198929 31.collab: EASL Clinical Practice Guidelines:Management of chronic" exact="hepatitis" post="B virus infection European Association for the Study of"/>
  <result pre="Ther.201644163410.1111/apt.1365927198929 31.collab: EASL Clinical Practice Guidelines:Management of chronic hepatitis B" exact="virus infection" post="European Association for the Study of the LiverJ. Hepatol.201767237039810.1016/j.jhep.2017.03.02128427875"/>
  <result pre="31.collab: EASL Clinical Practice Guidelines:Management of chronic hepatitis B virus" exact="infection" post="European Association for the Study of the LiverJ. Hepatol.201767237039810.1016/j.jhep.2017.03.02128427875"/>
  <result pre="Lamivudine plus Adefovir Therapy Compared with Lamivudine Alone in Preventing" exact="Hepatitis" post="B Reactivation in Lymphoma Patients with High Baseline HBV"/>
  <result pre="Compared with Lamivudine Alone in Preventing Hepatitis B Reactivation in" exact="Lymphoma" post="Patients with High Baseline HBV DNA during ChemotherapyPLoS One.201611e016421010.1371/journal.pone.016421027711135"/>
  <result pre="in HIV-infected patientsN. Engl. J. Med.200234681182010.1056/NEJMoa01203511893792 35.MiróOet al.Mitochondrial effects of" exact="HIV infection" post="on the peripheral blood mononuclear cells of HIV-infected patients"/>
  <result pre="HIV-infected patientsN. Engl. J. Med.200234681182010.1056/NEJMoa01203511893792 35.MiróOet al.Mitochondrial effects of HIV" exact="infection" post="on the peripheral blood mononuclear cells of HIV-infected patients"/>
  <result pre="J. Med.200234681182010.1056/NEJMoa01203511893792 35.MiróOet al.Mitochondrial effects of HIV infection on the" exact="peripheral" post="blood mononuclear cells of HIV-infected patients who were never"/>
  <result pre="with antiretroviralsClin. Infect. Dis.20043971071610.1086/42317615356787 36.LundKCPetersonLLWallaceKBAbsence of a Universal Mechanism of" exact="Mitochondrial" post="Toxicity by Nucleoside AnalogsAntimicrob. Agents Chemother.2007512531253910.1128/AAC.00039-0717470651 37.LópezSet al.Mitochondrial effects"/>
  <result pre="of antiretroviral therapies in asymptomatic patientsAntivir. Ther.20049475515040536 38.McComseyGBaiRMaaJFWongLJExtensive Investigations of" exact="Mitochondrial" post="DNA Genome in Lipoatrophy: Beyond mtDNA depletionJ. Acquir. Immune"/>
  <result pre="39.PeraireJet al.HIV-1 infected long-term non-progressors have milder mitochondrial impairment and" exact="lower" post="mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical"/>
  <result pre="non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in" exact="peripheral" post="blood mononuclear cells than typical progressorsCurr. HIV Res.2007546747310.2174/15701620778166245217896966 40.JacototEet"/>
  <result pre="mononuclear cells than typical progressorsCurr. HIV Res.2007546747310.2174/15701620778166245217896966 40.JacototEet al.The HIV-1" exact="viral" post="protein R induces apoptosis via a direct effect on"/>
  <result pre="poreJ. Exp. Med.2000191334610.1084/jem.191.1.3310620603 41.CasulaMet al.Mitochondrial DNA and RNA increase in" exact="peripheral" post="blood mononuclear cells from HIV-1- infected patients randomized to"/>
  <result pre="ribonucleic acid abundance and induces ultrastructural changes in cultured mouse" exact="muscle" post="cellsLab. Invest.1994718798847528833"/>
 </snippets>
</snippetsTree>
